Chemotherapy-free strategies in treating leukaemiation?
Dose escalation of REGN1979 in patients with relapsed and refractory B-NHL
CD-19 mutation frequency after blinatumomab treatment is lower than after CAR T-cell therapy
ADMIRAL trial results: Gilteritinib versus salvage chemotherapy in patients with FLT3-mutated relapsed/refractory AML
Multiple myeloma science from EHA 2019
Selinexor plus cytarabine and idarubicin in patients with relapsed/refractory acute myeloid leukaemia
ECHELON-1 study 3 year update: Frontline brentuximab vedotin with chemotherapy for stage 3/4 classical Hodgkin lymphoma
Controlling CRS-related coagulopathy improves the safety of CAR T-cell therapy for MM
Dasatinib-blinatumomab combination for the front-line treatment of adult Ph-positive ALL patients
CAR T-cell therapy for treating acute leukaemia
ICARIA results: Treating RRMM patients with isatuximab, pomalidomide and low-dose dexamethasone
HORIZON update: Using melflufen to treat RRMM patients refractory to daratumumab and/or pomalidomide
Safety and efficacy of escalating doses of Hu5F9-G4 with rituximab in patients with R/R DLBCL and indolent lymphoma
CLL12 trial: Ibrutinib in previously untreated, asymptomatic early-stage CLL
MOR208 plus lenalidomide in r-r diffuse large B-cell lymphoma
The changing landscape of AML
RESONATE-2: Five-year follow up of CLL patients receiving ibrutinib as first-line treatment
Myeloma highlights from EHA 2019
Inhibition of NADK strongly inhibits T-ALL cells from growing
Novel immunotherapy 5F9 plus rituximab well tolerated with rapid and durable responses in R/R DLBCL and indolent lymphomaung cancer
Venetoclax with bortezomib and dexamethasone shows good response but higher risk of treatment related death in RRMM
Acalabrutinib monotherapy shows significant benefit in relapsed or refractory chronic lymphocytic leukaemia
Imetelstat provides durable transfusion independence in heavily transfused non-del(5q) LR-MDS R/R to ESAS
D-VTd in induction prior to and consolidation after ASCT improves PFS and depth of response with acceptable safety
Venetoclax plus obinutuzumab improves PFS and MRD-negativity in patients with previously untreated CLL and comorbidities
Most pregnancies in CML patients resulted in normal childbirth: Analysis of 305 cases of the European Leukemia Net registry
Intervention for AML patients with MRD can result in improved survival
Use of maintenance therapy following ASCT and real world treatment patterns in multiple myeloma
